Literature DB >> 15212958

The oncogenic fusion protein EWS/NOR-1 induces transformation of CFK2 chondrogenic cells.

Christine Filion1, Yves Labelle.   

Abstract

The EWS/NOR-1 fusion protein is encoded by the t(9;22) chromosomal translocation found in approximately 75% of extraskeletal myxoid chondrosarcoma (EMC) tumors. The lack of cellular models in which the oncogenic properties of this fusion protein are expressed has seriously hampered the study of its role in the development of EMC. To generate such a cellular model, we have used the chondrogenic cell line CFK2. We show in this study that although stable expression of EWS/NOR-1 does not alter the population doubling time and the cell cycle distribution of CFK2 cells in subconfluent cultures, it induces their transformation as measured by growth beyond confluency and anchorage-independent growth in soft agarose medium. Glycosaminoglycan accumulation in CFK2(EWS/NOR-1) cell lines indicate that the fusion protein does not appear to interfere with the ability of CFK2 cells to differentiate into chondrocyte-like cells in vitro. These results support the hypothesis that the role of EWS/NOR-1 in EMC may be to disrupt the proliferation properties of cells involved in chondrogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212958     DOI: 10.1016/j.yexcr.2004.03.040

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.

Authors:  Christine Filion; Yves Labelle
Journal:  Tumour Biol       Date:  2012-05-18

Review 2.  The interplay of NR4A receptors and the oncogene-tumor suppressor networks in cancer.

Authors:  Jordan A Beard; Alexa Tenga; Taosheng Chen
Journal:  Cell Signal       Date:  2014-11-15       Impact factor: 4.315

3.  Regulation of oncogenic transcription factor hTAF(II)68-TEC activity by human glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Authors:  Sol Kim; Jungwoon Lee; Jungho Kim
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

4.  Primary intracranial extraskeletal myxoid chondrosarcoma: A case report and review of literature.

Authors:  Zi-You Zhu; Yu-Bo Wang; Han-Yi Li; Xin-Min Wu
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

5.  Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.

Authors:  Alex D Drilon; Sanjay Popat; Gauri Bhuchar; David R D'Adamo; Mary Louise Keohan; Cyril Fisher; Cristina R Antonescu; Samuel Singer; Murray F Brennan; Ian Judson; Robert G Maki
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

6.  The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.

Authors:  C Filion; T Motoi; A B Olshen; M Laé; R J Emnett; D H Gutmann; A Perry; M Ladanyi; Y Labelle
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

7.  Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib.

Authors:  Silvia Stacchiotti; Gian Paolo Dagrada; Carlo Morosi; Tiziana Negri; Antonella Romanini; Silvana Pilotti; Alessandro Gronchi; Paolo G Casali
Journal:  Clin Sarcoma Res       Date:  2012-10-11

8.  Extraskeletal myxoid chondrosarcoma: A case series and review of the literature.

Authors:  Michael P Fice; Linus Lee; Pavan Kottamasu; Abdullah Almajnooni; Matthew R Cohn; Charles A Gusho; Steven Gitelis; Alan T Blank
Journal:  Rare Tumors       Date:  2022-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.